ClinicalTrials.gg
SuspendedNCT02769130Updated Jul 30, 2019

Pilot Trial: the Safety and Feasibility of Losartan for Pulmonary Vein Stenosis

A Phase 1/2 interventional study of Losartan in Pulmonary Vein Stenosis and Children, sponsored by The Hospital for Sick Children. Suspended at 1 site in Canada. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2019-07-30.

Sponsored by The Hospital for Sick Children · Phase 1/2, Interventional, and Treatment

How we know

Why this study was suspended
Due to Health Canada losartan recall, a new formulation being added to the protocol/ temporary suspension

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

This pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis.

It is an open label single arm interventional study. The patient population involves pediatric patients with stenosis in 2 or more pulmonary veins. Patients will be given losartan for 1 year. Outcomes include measures of safety/adverse events and progression of pulmonary vein stenosis.

Read the detailed description

This pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis.

Large animal studies have demonstrated that losartan can ameliorate the progression of pulmonary vein stenosis in a surgical model of pulmonary vein stenosis.

There is no safety data for losartan in children \< 6months of age or in children with pulmonary vein stenosis. Therefore, this study will test the safety and feasibility of losartan in children in an open label single arm interventional study.

Patient inclusion criteria includes stenosis involving 2 or more pulmonary veins. Patients who are consented into the trial with be on losartan therapy for one year. They will undergo study visits every 3 months. Patients will be screened for adverse events through biochemical tests, routine clinical tests and questionnaires.

An exploratory efficacy analysis will compare progression of pulmonary vein stenosis in children enrolled in losartan to a contemporary cohort of children with pulmonary vein stenosis, who did not receive losartan.

02

Conditions studied

  • Pulmonary Vein Stenosis
  • Children
03

In context

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 82 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stenosis involving 2 or more pulmonary veins
  • Consent of parent/legal guardian or child(when appropriate)

Exclusion criteria

Exclusion Criteria:

  • History of angioedema or allergic reaction to angiotensin converting enzyme inhibitors
  • corrected gestational age of less than 40 weeks
  • severe renal dysfunction
  • pregnancy
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Losartan

    Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins. Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year.

    Drug: Losartan

Interventions

  • Losartan is given for 12 months

    Also known as: Cozaar

06

What researchers measure

Primary outcomes

  1. Safety:Number of participants with adverse events

    adverse events include hypotension, hyperkalemia, renal dysfunction

    Time frame: 12 months

  2. Feasibility:Number of participants eligible and recruited

    includes patient recruitment and compliance with protocol

    Time frame: 12 months

Secondary outcomes

  1. Progression of pulmonary vein stenosis: survival

    Progression of pulmonary vein stenosis measures include survival, morbidity and evidence of progression on clinical tests

    Time frame: 12 months

07

Study locations

1 site
  • Hospital for Sick Children
    Toronto, Ontario m5g 0a4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of May 2021 and a completion of May 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2016
First posted
May 11, 2016
Start
May 2016
Primary completionEst.
May 2021
CompletionEst.
May 2021
Last update
Jul 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02769130
Responsible party
Christopher Caldarone (Surgeon in Chief, The Hospital for Sick Children) — Principal investigator
First posted
May 11, 2016
Start date
May 2016
Primary completion
May 2021 (estimated)
Completion
May 2021 (estimated)
Last update
Jul 30, 2019

Study contacts

Christopher A Caldarone, MD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion